Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 trial of selinexor + pomalidomide + dexamethasone versus elotuzumab + pomalidomide + dexamethasone in relapsed or refractory multiple myeloma
2024-518304-53-00Phase 3Authorised
- Sponsor
- European Myeloma Network B.V.
- Start
- Oct 2024
- Modality
- Small Molecules
- Countries
- 7
01
Overview
Phase 3, randomised, open-label trial of selinexor in multiple myeloma (MM) (2 arms), sponsored by European Myeloma Network B.V. Primary endpoint: Progression-free survival (PFS). Planned start Oct 2024; status: authorised.
02
Drugs
selinexor
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on 2024-518304-53-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-518304-53-00.